In the VICTOR trial, patients with PI3KCA-positive colorectal cancer who took aspirin had a lower cancer recurrence compared to those with a wild-type PI3KCA gene.
Analysis of 18F FDG-PET standardized uptake values may be a useful technique for predicting survival in patients with inoperable stage III non–small-cell lung carcinoma, according to a new study.
A mutation of the PAX5 gene has been found to play an important role in inherited cases of B-cell precursor acute lymphoblastic leukemia (B-ALL). The mutation was isolated in two unrelated families with high propensity for B-ALL.
The use of GM2-KLH/QS-21 vaccination in stage II melanoma patients did not improve outcomes, according to the results of the EORTC 18961 phase III trial.
Gilead Sciences has submitted an NDA to the FDA for its new drug idelalisib, for the use in patients with indolent non-Hodgkin lymphoma that is refractory to rituximab and chemotherapy.
Pomalidomide, an immunomodulatory drug, combined with low-dose dexamethasone improved progression-free survival in patients with refractory or relapsed and refractory multiple myeloma compared with standard of care high-dose dexamethasone, according to a new study.
Researchers have identified a novel pathway that promotes bone metastasis of small-cell lung cancer (SCLC). The study is in mice, but points to a potential target that could be exploited to control or prevent metastatic disease.
In order for malignancies to establish in metastatic sites, cancer cells must acquire attributes of those sites; specifically how this occurs in many cancers is relatively unknown, but a new study implicates the stroma of certain breast cancer tumors in the development of bone metastases.
The results of the study comparing Aveo’s tivozanib to sorafenib for the treatment of metastatic renal cell carcinoma showed no improvement in overall survival, the basis for the FDA’s rejection of the company’s new drug application earlier this year.
Evidence continues to mount that discontinuing imatinib treatment for chronic myeloid leukemia (CML) in the chronic phase is safe. A new phase II Dutch and Belgian study showed only about two-thirds of patients relapsed after discontinuing treatment with imatinib and cytarabine, and all patients remained sensitive to imatinib after relapse.